Human BAFF Antibody - Belimumab Biosimilar

Human IgG1 - CAS #356547-88-1

ABOUT

Anti-human BAFF - Belimumab biosimilar - CAS #356547-88-1

Anti-hBAFF-hIgG1 is a biosimilar antibody of Belimumab, a human BAFF (B cell activating factor) antibody that blocks BAFF signaling. This monoclonal antibody (mAb) is FDA-approved for the treatment of patients with systemic lupus erythematosus (SLE) and lupus nephritis.

More details More details


Anti-hBAFF-hIgG1 comprises the variable region of Belimumab and the IgG1 constant region of Belimumab, mediating high effector functions. 

This antibody can be used together with HEK-Blue™ BCMA cells for screening and neutralization assays to block BAFF/BCMA signaling induced by recombinant human BAFF (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

All products are for research use only, and not for human or veterinary use.

Binding of Anti-hBAFF Belimumab
Binding of Anti-hBAFF Belimumab

SPECIFICATIONS

Specifications

Target

BAFF

Target species

Human

Applications

Neutralization assay (tested), ELISA

Species
Human
Isotype
hIgG1
lambda
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Belimumab
CAS number
356547-88-1
Synonyms
HGS1006
GSK1550188
Benlysta
Molecular weight
144 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Sterility

0.2 µm filtration

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hBAFF-hIgG1
  • Cat code: 
    hbaff-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Belimumab background

Belimumab (aka Benlysta) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human B-cell-activating factor (BAFF, CD257) cytokine [1]. By binding to BAFF, Belimumab prevents it from interacting with its receptors BAFF-R, TACI, and BCMA on the surface of immune cells, thus inhibiting its downstream functions, notably mature B cell development, immunoglobulin (Ig) class switching, and plasmocyte survival.
BAFF is a member of the tumor necrosis factor cytokine family [2]. Together with the related cytokine APRIL (A proliferation-inducing ligand) and two other receptors, BCMA and TACI, it belongs to the BAFF-APRIL system, which is critical for B-cell function. Dysregulation in the BAFF-APRIL axis is associated with autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), as well as blood cancers [2].
Belimumab is approved by the FDA for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis [1,3]. Its use as a cancer treatment is under clinical evaluation [4].
 

​References:

1. Levy R.A., et al., 2021. 10 years of belimumab experience: what have we learnt? Lupus. 30(11):1705-1721.
2. Ullah M.A. & Mackay F., 2023. The BAFF/APRIL system in cancer. Cancers. 15:1791.
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125370s085lbl.pdf.
4. NCT05069051 (accessed October 2025). 

You may also need

Citations

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?